These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
422 related articles for article (PubMed ID: 22635028)
1. Silencing Wnt2B by siRNA interference inhibits metastasis and enhances chemotherapy sensitivity in ovarian cancer. Wang H; Fan L; Xia X; Rao Y; Ma Q; Yang J; Lu Y; Wang C; Ma D; Huang X Int J Gynecol Cancer; 2012 Jun; 22(5):755-61. PubMed ID: 22635028 [TBL] [Abstract][Full Text] [Related]
2. MiR-338-3p Enhances Ovarian Cancer Cell Sensitivity to Cisplatin by Downregulating WNT2B. Niu Q; Liu Z; Gao J; Wang Q Yonsei Med J; 2019 Dec; 60(12):1146-1156. PubMed ID: 31769245 [TBL] [Abstract][Full Text] [Related]
3. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway. Zhang C; Wang M; Shi C; Shi F; Pei C Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351 [TBL] [Abstract][Full Text] [Related]
4. Targeted inhibition of phosphatidyl inositol-3-kinase p110β, but not p110α, enhances apoptosis and sensitivity to paclitaxel in chemoresistant ovarian cancers. Jeong JY; Kim KS; Moon JS; Song JA; Choi SH; Kim KI; Kim TH; An HJ Apoptosis; 2013 Apr; 18(4):509-20. PubMed ID: 23371322 [TBL] [Abstract][Full Text] [Related]
5. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs. Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496 [TBL] [Abstract][Full Text] [Related]
6. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun. Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707 [TBL] [Abstract][Full Text] [Related]
7. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis. Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Mo QQ; Chen PB; Jin X; Chen Q; Tang L; Wang BB; Li KZ; Wu P; Fang Y; Wang SX; Zhou JF; Ma D; Chen G Acta Pharmacol Sin; 2013 Apr; 34(4):541-8. PubMed ID: 23474708 [TBL] [Abstract][Full Text] [Related]
9. ERp57‑small interfering RNA silencing can enhance the sensitivity of drug‑resistant human ovarian cancer cells to paclitaxel. Li S; Zhao X; Chang S; Li Y; Guo M; Guan Y Int J Oncol; 2019 Jan; 54(1):249-260. PubMed ID: 30431082 [TBL] [Abstract][Full Text] [Related]
10. PTEN overexpression improves cisplatin-resistance of human ovarian cancer cells through upregulating KRT10 expression. Wu H; Wang K; Liu W; Hao Q Biochem Biophys Res Commun; 2014 Feb; 444(2):141-6. PubMed ID: 24434152 [TBL] [Abstract][Full Text] [Related]
11. Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling. Zhang K; Song H; Yang P; Dai X; Li Y; Wang L; Du J; Pan K; Zhang T Cell Prolif; 2015 Apr; 48(2):249-58. PubMed ID: 25643607 [TBL] [Abstract][Full Text] [Related]
12. SMAD3 inducing the transcription of STYK1 to promote the EMT process and improve the tolerance of ovarian carcinoma cells to paclitaxel. Shi Y; Zhang J; Liu M; Huang Y; Yin L J Cell Biochem; 2019 Jun; 120(6):10796-10811. PubMed ID: 30701575 [TBL] [Abstract][Full Text] [Related]
13. PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer. Risnayanti C; Jang YS; Lee J; Ahn HJ Sci Rep; 2018 May; 8(1):7498. PubMed ID: 29760419 [TBL] [Abstract][Full Text] [Related]
14. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells. Li Y; Sun J; Gao S; Hu H; Xie P Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518 [TBL] [Abstract][Full Text] [Related]
15. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways]. Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551 [TBL] [Abstract][Full Text] [Related]
16. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling. Chau WK; Ip CK; Mak AS; Lai HC; Wong AS Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058 [TBL] [Abstract][Full Text] [Related]
17. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells. Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135 [TBL] [Abstract][Full Text] [Related]
18. Resistance to chemotherapy-induced apoptosis via decreased caspase-3 activity and overexpression of antiapoptotic proteins in ovarian cancer. Yang X; Zheng F; Xing H; Gao Q; Wei W; Lu Y; Wang S; Zhou J; Hu W; Ma D J Cancer Res Clin Oncol; 2004 Jul; 130(7):423-8. PubMed ID: 15156398 [TBL] [Abstract][Full Text] [Related]
19. HE4 promotes collateral resistance to cisplatin and paclitaxel in ovarian cancer cells. Ribeiro JR; Schorl C; Yano N; Romano N; Kim KK; Singh RK; Moore RG J Ovarian Res; 2016 May; 9(1):28. PubMed ID: 27184254 [TBL] [Abstract][Full Text] [Related]
20. HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response. Liu X; Yu Y; Zhang J; Lu C; Wang L; Liu P; Song H Cell Physiol Biochem; 2018; 48(4):1505-1518. PubMed ID: 30071534 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]